Further studies are needed to identify adjuvant therapy strategies, such as mTOR inhibitors (e.g., rapamycin) or AKT inhibitors, to enhance therapeutic efficacy in PCa therapy. The gene discussed is MTOR; the disease is posterior cortical atrophy.